Latest
Hot
2
$CureVac (CVAC.US)$
As of 2024, CureVac's COVID-19 vaccine is undergoing clinical trials. Currently, the second-generation mRNA COVID-19 vaccine developed in collaboration with GSK is in Phase II trials.
Progress and Trial Data
In the Phase II clinical trials, CureVac's monovalent vaccine CV0601 and bivalent vaccine CV0701 both showed positive results. The monovalent vaccine, targeting the Omicron BA.4-5 variant, demonstrated a fi...
As of 2024, CureVac's COVID-19 vaccine is undergoing clinical trials. Currently, the second-generation mRNA COVID-19 vaccine developed in collaboration with GSK is in Phase II trials.
Progress and Trial Data
In the Phase II clinical trials, CureVac's monovalent vaccine CV0601 and bivalent vaccine CV0701 both showed positive results. The monovalent vaccine, targeting the Omicron BA.4-5 variant, demonstrated a fi...
1
4
$Akebia Therapeutics (AKBA.US)$
Commercial value
Healthy balance sheet
New market
This is buy and hold for long
What is your best price today?
Commercial value
Healthy balance sheet
New market
This is buy and hold for long
What is your best price today?
$Moderna (MRNA.US)$ stock gained 7.8% Thursday, its virtual R&D day, which began at 8 a.m. Eastern. It plans to announce the development of a vaccine candidate that will protect against Covid-19 and the flu, to be known as mRNA-1073.
Moderna was a very different company at the time of its last virtual R&D day in September of 2020. Still a clinical-stage company at the time, Moderna had no authorized or approved products. That changed months later, when the U.S. Food and Drug Administration authorized Moderna’s Covid-19 vaccine, which is expected to bring in $20.1 billion in revenues this year alone.
Its stock price has been up more than 300% this year.
Just to mention, another vaccine maker $Novavax (NVAX.US)$ had also initiated an early-stage study to test its combined flu and COVID-19 vaccine. However, the same scenario didn't show on its stock price. Kinda tricky.
Source: Moderna Stock Jumped Because It Just Unveiled a Two-in-One Vaccine for Covid and the Flu
Moderna was a very different company at the time of its last virtual R&D day in September of 2020. Still a clinical-stage company at the time, Moderna had no authorized or approved products. That changed months later, when the U.S. Food and Drug Administration authorized Moderna’s Covid-19 vaccine, which is expected to bring in $20.1 billion in revenues this year alone.
Its stock price has been up more than 300% this year.
Just to mention, another vaccine maker $Novavax (NVAX.US)$ had also initiated an early-stage study to test its combined flu and COVID-19 vaccine. However, the same scenario didn't show on its stock price. Kinda tricky.
Source: Moderna Stock Jumped Because It Just Unveiled a Two-in-One Vaccine for Covid and the Flu
40
17
12
Pharmaceutical stocks started to rise again is only a matter of time With all sorts of biotech companies have launched the vaccine, main pharmaceutical shares is expected to benefit from Moderna and companies such as Pfizer has been rising over the past year, but in the past two months, because of the financial impact caused by vaccine sales far above analysts' expectations, their share prices have appeared almost exponential increases.
Investors now focus on future sustainability of vaccine revenue.
Pfizer noted that it expects to recommend a third booster shot later this year, and that the rising number of cases of the mutant strain could keep demand for additional vaccines high This month,Moderna increased its weighting to the 3% ceiling from 0.85%, while Pfizer increased its weighting to 1.96% from 0.47%. The overall weighting of the healthcare sector in the BUZZ index rose to 9.8% from 5.7%, indicating growing investor confidence in the sector....
Investors now focus on future sustainability of vaccine revenue.
Pfizer noted that it expects to recommend a third booster shot later this year, and that the rising number of cases of the mutant strain could keep demand for additional vaccines high This month,Moderna increased its weighting to the 3% ceiling from 0.85%, while Pfizer increased its weighting to 1.96% from 0.47%. The overall weighting of the healthcare sector in the BUZZ index rose to 9.8% from 5.7%, indicating growing investor confidence in the sector....
pfizer promising. people need vaccination before traveling and enjoy holiday. kids also can receive vaccination. booster will be needed.
1
Moderna COVID-19 Vaccine $Moderna (MRNA.US)$ gets Health Canada Approval in Children 12 and Up!!
Vaccine stocks will continue to rally to the top and is certainly a To-Buy ✅
$Moderna (MRNA.US)$ is seemingly poised to cater to the market with its amazing mRNA technology which can be more quickly adapted to fight the newer variants. This means Moderna’s highly lucrative Covid-19 vaccine revenues are likely to continue for the foreseeable future ahead. ...
Vaccine stocks will continue to rally to the top and is certainly a To-Buy ✅
$Moderna (MRNA.US)$ is seemingly poised to cater to the market with its amazing mRNA technology which can be more quickly adapted to fight the newer variants. This means Moderna’s highly lucrative Covid-19 vaccine revenues are likely to continue for the foreseeable future ahead. ...
9
5
4
Vaccine stocks are still considered quite volatile in my opinion. Many companies are still trying out different ways to manufacture the best vaccine which has the minimum side effects and the best results against Covid. For now, the mRNA vaccines like $Pfizer (PFE.US)$ and $Moderna (MRNA.US)$ are the current market best vaccines and are/will be undoubtedly approved by FDA amidst the increasing number of Covid cases to boost confidence in taking vaccines. It is more of a hard sell way to push people to take these high-efficacy vaccines. Thus, in short run, these mRNA companies will show a bullish trend but will still fluctuate at times since there have been negative news that such vaccines can cause deaths and increased heart diseases. The future for covid vaccines IS definitely still uncertain. Who knows if there is going to be a sudden competitor who can come up with the best vaccin...
8
Net buying of More than $400m of American depositary receipts by US retail investors of Chinese companies in the past week was the highest in five years, peaking on Monday, led by e-commerce giant Alibaba The research house's Vanda Rack unit is understood to monitor retail trading activity in 9,000 individual stocks and ETFs in the US.
According to Vanda, U.S. retail buying of Alibaba shares was more than double that of pharmaceutical giant Pfizer over the same period, even though Pfizer received full approval for its coronavirus vaccine from the U.S. Food and Drug Administration on Monday....
According to Vanda, U.S. retail buying of Alibaba shares was more than double that of pharmaceutical giant Pfizer over the same period, even though Pfizer received full approval for its coronavirus vaccine from the U.S. Food and Drug Administration on Monday....
1